COMPASS Pathways plc
NASDAQ:CMPSMedical - Care Facilities
+$0.02 today
- Market cap
- $1.15B
- Beta
- 2.51
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$1.63
Volume 2.35M
Average 4.09M
CMPS Net Income
Bottom-line profit after all expenses, interest, and taxes.
COMPASS Pathways plcNASDAQ: CMPS
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns positive
Q1 FY2026 net income was $91.05M, compared with -$17.86M a year earlier. Trailing-twelve-month net income was -$178.95M.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$68.62M (+76.2%) for the fiscal year ending Dec 2026, a step up from the -85.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $91.05M+197.0% QoQ
- Last fiscal yearDec 2025
- -$287.86M-85.6% YoY
- LTMMar 2026
- -$178.95M-29.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +609.7% | +5.8% | -603.9 pp |
| 1 year | -85.6% | +76.2% | +161.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (287.86M) USD
- Year-over-year change
- -85.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (287.86M) | -85.6% |
| FY2024 | 2024-12-31 | (155.12M) | -30.9% |
| FY2023 | 2023-12-31 | (118.46M) | -29.5% |
| FY2022 | 2022-12-31 | (91.51M) | -27.5% |
| FY2021 | 2021-12-31 | (71.74M) | — |
Net Income vs competitors
How CMPS compares with its peers on the latest reported figures
- CMPS's LTM Mar 2026 net income of -$178.95M is the 6th highest of the 11 companies compared; the peer median is -$153.38M.
- Its year-over-year change of -29.9% is the 4th highest of 10, against a peer median of -34.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $362.23M | +38.7% | — | 30.1% | |
| LTM Jun 2026 | $181.27M | +0.2% | -4.4% | 18.9% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | -$39.17M | — | — | — |
| LTM Mar 2026 | -$56.41M | -34.0% | — | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$107.28M | -34.6% | — | 536.4% |
| LTM Mar 2026 | -$178.95M | -29.9% | — | — | |
| LTM Mar 2026 | -$199.48M | -146.3% | — | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | -$337.48M | -100.8% | — | — |
| LTM Sep 2026 | -$359.43M | -31.6% | — | — | |
| LTM Jun 2026 | -$394.35M | -3611.7% | — | — | |
| LTM Jun 2026 | -$511.45M | -6.8% | — | 14191.2% | |
| Peer median (excluding CMPS) | -$153.38M | -34.0% | -4.4% | 283.3% | |
Competitors are the stored peer set for CMPS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 44.03M | 65.05M | 87.52M | 119.04M | 118.44M |
| Selling, General & Admin | 39.19M | 45.35M | 49.4M | 59.17M | 60.6M |
| Operating Expenses | 83.22M | 110.4M | 136.92M | 178.21M | 179.04M |
| Depreciation & Amortization | 175K | 330K | 242K | 233K | 216K |
| EBITDA | (71.37M) | (90.77M) | (115.24M) | (148.82M) | (285.6M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (83.22M) | (110.4M) | (136.92M) | (178.21M) | (179.04M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 4.62M | 8.27M | 7.18M |
| Interest Expense | 0 | 0 | 2.2M | 4.48M | 4.52M |
| Other Income / Expenses | 11.68M | 19.31M | 19.24M | 24.68M | (111.3M) |
| Income Before Tax | (71.54M) | (91.1M) | (117.68M) | (153.53M) | (290.34M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 199K | 408K | 780K | 1.59M | (2.47M) |
| Net Income | (71.74M) | (91.51M) | (118.46M) | (155.12M) | (287.86M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.79) | (2.16) | (2.32) | (2.30) | (3.08) |
| EPS (Diluted) | (1.79) | (2.16) | (2.32) | (2.30) | (3.08) |
| Weighted Avg Shares | 40M | 42.44M | 51.03M | 67.48M | 93.5M |
| Weighted Avg Shares (Diluted) | 40M | 42.44M | 51.03M | 67.48M | 93.5M |
COMPASS Pathways plc
NASDAQ:CMPS
Intrinsic Alpha fair value
Locked
Current Price
$8.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.